Neurodegenerative disease Archives

News and Trends 17 Nov 2022

FundaMental Pharma launches with €10M to advance first-in-class neuroprotectant

FundaMental Pharma GmbH, a preclinical neuroscience company spun out of Heidelberg University in Germany, has launched with €10 million ($10.4 million) in seed financing. The funding was led by BioGeneration Ventures (BGV) and Thuja Capital, with participation from other investors, including coparion and High-Tech Gründerfonds (HTGF). Built on the research of Hilmar Bading and Jing […]

November 17, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

BrainEver and 3P Biopharmaceuticals developing drug with hopes to cure ALS

3P BioPharmaceuticals and BrainEver are to collaborate on developing hEng1, a recombinant homeoprotein, to treat pathologies such as amyotrophic lateral sclerosis (ALS) or Parkinson’s disease. 3P BioPharmaceuticals is a contract development and manufacturing organization (CDMO) specializing in the process development and cGMP manufacturing of biological products, and BrainEver is a French biotechnology company focusing on […]

November 15, 2022 - 2 minutesmins - By Jim Cornall

Startup Scout 10 Nov 2022

ResQ Biotech is using bacteria to discover Alzheimer’s treatments

Protein misfolding underlies many incurable conditions such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The Greek startup ResQ Biotech is harnessing bacteria to test potential peptide treatments for these diseases. There are many diseases that involve the faulty processing of proteins in the cell, leading the proteins to clump together and damage the tissue. […]

November 10, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 10 Nov 2022

Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS

NRG Therapeutics, Ltd. has closed a £16 million ($18.2 million) series A financing. The funding was led by Omega Funds and joined by additional new investor Brandon Capital and founding investor Parkinson’s Virtual Biotech. NRG Therapeutics is using mitochondrial biology to develop disease-modifying therapeutics to slow or halt the progression of neurodegenerative disorders such as […]

November 10, 2022 - 3 minutesmins - By Jim Cornall

centogene rare diseases diagnostic ipo nasdaq

News and Trends 4 Nov 2022

Centogene launches rare and neurodegenerative disease Biodata Network

German company, Centogene N.V., today (November 4) announced its launch of Biodata Network, a portfolio of data-driven partnering solutions including licenses and insight report for biopharma and research institutions. The company, which works to find data-driven answers in rare and neurodegenerative diseases, wants to offer increased access to its insights. To do this, it has […]

November 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 29 Sep 2022

Human cells can now help scientists accelerate cure for neurodegenerative diseases

Cell products providing a scalable source of human cells can now help scientists study neurogenerative diseases in human context. UK-based, cell-coding company, bit.bio announced the expansion to its portfolio today (September 29) with disease model, ioGlutamatergic Neurons TDP-43 and early access to its ioMicroaglia cell product. Despite research efforts and funding, bit.bio says the development […]

September 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Sep 2022

Promising MND drug slows disease progression

Scientists in the U.K. believe a new genetically-targeted therapy to treat motor neurone disease (MND) could be a turning point for patient care. Results from a phase 3 clinical trial showed significant physical benefits for patients after 12 months. Researchers from the Sheffield Institute for Translational Neuroscience (SITraN) found that patients with a faulty SOD1 […]

September 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 21 Sep 2022

NodThera reveals positive results for inflammasome inhibitors

Biotech company NodThera has announced positive phase 1 clinical readouts for its first and second clinical candidates, NT-0796 and NT-0249. A phase 1 study has been completed for NT-0796, confirming brain penetration with excellent pharmacokinetic (PK) and pharmacodynamic (PD) profiles and for NT-0249, dosing of the phase 1 single ascending dose cohorts has been completed, […]

September 21, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

Collaboration to explore gene therapy products for neurodegenerative disorders

Coave Therapeutics is collaborating with the Institute of Neurodegenerative Diseases (IMN) of Bordeaux to develop gene therapy proteins targeting protein degradation in neurodegenerative disorders. The IMN is a joint research unit associating the University of Bordeaux and the French National Centre of Scientific Research (CNRS) developing gene therapy programs targeting protein degradation in neurodegenerative disorders. […]

September 14, 2022 - 3 minutesmins - By Liza Laws

News and Trends 6 Sep 2022

IRLAB’s partner Ipsen starts mesdopetam clinical studies

IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, says its partner, Ipsen, has initiated clinical studies with drug candidate mesdopetam in accordance with its development plan. These are standard clinical pharmacokinetic studies that will run in parallel to the phase IIb study with […]

September 6, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Researchers identify possible target for type of sporadic ALS

Researchers have published two papers describing how they identified a potential new pathway for treating a sporadic form of amyotrophic lateral sclerosis (ALS). The studies were published as part of a cooperative research agreement between the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, and the Swiss biotech […]

August 31, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 31 Aug 2022

Research shows TikoMed’s ILB has the potential to treat neurodegenerative diseases including ALS

Peer-review research published in Frontiers in Pharmacology supports the broad spectrum mechanism of action of Swedish biopharma company TikoMed’s ILB neuroprotective drug platform. In multiple preclinical and clinical studies across a variety of neuroinflammation-driven diseases, the low molecular weight dextran sulfate compound both mobilized and modulated naturally occurring tissue repair mechanisms and restored cellular homeostasis […]

August 31, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Neurodegenerative disease

FundaMental Pharma launches with €10M to advance first-in-class neuroprotectant

BrainEver and 3P Biopharmaceuticals developing drug with hopes to cure ALS

ResQ Biotech is using bacteria to discover Alzheimer’s treatments

Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS

Centogene launches rare and neurodegenerative disease Biodata Network

Human cells can now help scientists accelerate cure for neurodegenerative diseases

Promising MND drug slows disease progression

NodThera reveals positive results for inflammasome inhibitors

Collaboration to explore gene therapy products for neurodegenerative disorders

IRLAB’s partner Ipsen starts mesdopetam clinical studies

Researchers identify possible target for type of sporadic ALS

Research shows TikoMed’s ILB has the potential to treat neurodegenerative diseases including ALS

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!